SG11201701809UA - Cancer cell-specific antibody, anticancer drug and cancer testing method - Google Patents
Cancer cell-specific antibody, anticancer drug and cancer testing methodInfo
- Publication number
- SG11201701809UA SG11201701809UA SG11201701809UA SG11201701809UA SG11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA SG 11201701809U A SG11201701809U A SG 11201701809UA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- specific antibody
- testing method
- anticancer drug
- cancer cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 238000012360 testing method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014182760 | 2014-09-08 | ||
| JP2014260727 | 2014-12-24 | ||
| PCT/JP2015/075425 WO2016039321A1 (en) | 2014-09-08 | 2015-09-08 | Cancer-cell-specific antibody, anticancer agent, and cancer testing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701809UA true SG11201701809UA (en) | 2017-04-27 |
Family
ID=55459067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701809UA SG11201701809UA (en) | 2014-09-08 | 2015-09-08 | Cancer cell-specific antibody, anticancer drug and cancer testing method |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10471146B2 (en) |
| EP (1) | EP3192527A4 (en) |
| JP (2) | JP6781507B2 (en) |
| KR (1) | KR102029248B1 (en) |
| CN (1) | CN106999576B (en) |
| AU (2) | AU2015313268B2 (en) |
| BR (1) | BR112017004446A2 (en) |
| CA (1) | CA2960466C (en) |
| IL (1) | IL250848B (en) |
| MY (1) | MY187050A (en) |
| RU (1) | RU2753512C2 (en) |
| SG (1) | SG11201701809UA (en) |
| WO (1) | WO2016039321A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017154868A1 (en) * | 2016-03-08 | 2017-09-14 | 国立研究開発法人国立がん研究センター | Anti-tmem-180 antibody, anticancer agent, and test method for cancer |
| JP7209284B2 (en) | 2016-08-15 | 2023-01-20 | 国立研究開発法人国立がん研究センター | Antibody that binds to TMEM132A, anticancer agent, and method for testing cancer |
| KR20190131538A (en) * | 2017-03-31 | 2019-11-26 | 가부시키가이샤 히로츠 바이오 사이언스 | Predictive and / or recurrence monitoring of treatment effects in cancer patients |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019136300A2 (en) * | 2018-01-05 | 2019-07-11 | Immunext, Inc. | Anti-mct1 antibodies and uses thereof |
| WO2021087114A1 (en) * | 2019-10-29 | 2021-05-06 | University Of Florida Research Foundation, Incorporated | Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use |
| WO2022098662A2 (en) * | 2020-11-03 | 2022-05-12 | Twist Bioscience Corporation | Methods and compositions relating to chemokine receptor variants |
| WO2023105087A1 (en) * | 2021-12-10 | 2023-06-15 | Tubulis Gmbh | Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors |
| CN116769729A (en) * | 2023-06-05 | 2023-09-19 | 中国科学技术大学 | Antibodies or antigen binding fragments targeting CD150 and uses thereof |
| CN117567635B (en) * | 2024-01-16 | 2024-05-14 | 恺佧生物科技(上海)有限公司 | Antibodies against Cas9 enzymes and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009045201A1 (en) * | 2006-08-02 | 2009-04-09 | Biogen Idec Ma Inc. | Cancer stem cells |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| US8080415B2 (en) * | 2008-09-26 | 2011-12-20 | Eureka Therapeutics, Inc. | Modified host cells and uses thereof |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| EP2411413B1 (en) * | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| US20110195848A1 (en) * | 2010-01-08 | 2011-08-11 | Roopra Avtar S | Gene expression and breast cancer |
| KR20130066682A (en) * | 2010-10-05 | 2013-06-20 | 다이이찌 산쿄 가부시키가이샤 | Antibody targeting osteoclast-related protein siglec-15 |
| CA2866252A1 (en) | 2012-03-06 | 2013-09-12 | Order-Made Medical Research Inc. | Pharmaceutical composition for treating cancer |
| US20150226744A1 (en) * | 2012-09-17 | 2015-08-13 | Ait Austrian Institute Of Technology Gmbh | Colon Cancer Diagnostic Method and Means |
| WO2017154868A1 (en) * | 2016-03-08 | 2017-09-14 | 国立研究開発法人国立がん研究センター | Anti-tmem-180 antibody, anticancer agent, and test method for cancer |
-
2015
- 2015-09-08 CN CN201580048202.6A patent/CN106999576B/en active Active
- 2015-09-08 JP JP2016547444A patent/JP6781507B2/en active Active
- 2015-09-08 AU AU2015313268A patent/AU2015313268B2/en active Active
- 2015-09-08 IL IL250848A patent/IL250848B/en unknown
- 2015-09-08 US US15/509,269 patent/US10471146B2/en active Active
- 2015-09-08 CA CA2960466A patent/CA2960466C/en active Active
- 2015-09-08 MY MYPI2017700758A patent/MY187050A/en unknown
- 2015-09-08 EP EP15840271.9A patent/EP3192527A4/en active Pending
- 2015-09-08 WO PCT/JP2015/075425 patent/WO2016039321A1/en active Application Filing
- 2015-09-08 RU RU2017111584A patent/RU2753512C2/en active
- 2015-09-08 SG SG11201701809UA patent/SG11201701809UA/en unknown
- 2015-09-08 BR BR112017004446-3A patent/BR112017004446A2/en active Search and Examination
- 2015-09-08 KR KR1020177008443A patent/KR102029248B1/en active IP Right Grant
-
2018
- 2018-12-05 AU AU2018274932A patent/AU2018274932B2/en active Active
-
2019
- 2019-09-23 US US16/578,861 patent/US11524074B2/en active Active
-
2020
- 2020-10-13 JP JP2020172408A patent/JP6980075B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170260284A1 (en) | 2017-09-14 |
| MY187050A (en) | 2021-08-27 |
| US11524074B2 (en) | 2022-12-13 |
| US20200078458A1 (en) | 2020-03-12 |
| AU2015313268B2 (en) | 2018-12-20 |
| US10471146B2 (en) | 2019-11-12 |
| IL250848B (en) | 2022-07-01 |
| JP6781507B2 (en) | 2020-11-04 |
| RU2753512C2 (en) | 2021-08-17 |
| RU2017111584A3 (en) | 2018-10-10 |
| CN106999576B (en) | 2021-09-03 |
| BR112017004446A2 (en) | 2018-02-27 |
| AU2018274932B2 (en) | 2020-11-05 |
| IL250848A0 (en) | 2017-04-30 |
| JP2021019616A (en) | 2021-02-18 |
| CA2960466C (en) | 2023-09-05 |
| WO2016039321A1 (en) | 2016-03-17 |
| KR20170047351A (en) | 2017-05-04 |
| JPWO2016039321A1 (en) | 2017-06-22 |
| AU2018274932A1 (en) | 2019-01-03 |
| CN106999576A (en) | 2017-08-01 |
| RU2017111584A (en) | 2018-10-10 |
| EP3192527A4 (en) | 2018-04-11 |
| AU2015313268A1 (en) | 2017-03-23 |
| KR102029248B1 (en) | 2019-10-08 |
| CA2960466A1 (en) | 2016-03-17 |
| JP6980075B2 (en) | 2021-12-15 |
| EP3192527A1 (en) | 2017-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304772A (en) | Antibodies, uses and methods | |
| ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
| SG11201701809UA (en) | Cancer cell-specific antibody, anticancer drug and cancer testing method | |
| IL252015A0 (en) | Antibody drug conjugates | |
| EP3150707A4 (en) | Pancreatic cancer detection kit, device, and detection method | |
| IL251938A0 (en) | Anti-cs1 antibodies and antibody drug conjugates | |
| IL250189A0 (en) | Anti-cdh6 antibody drug conjugates | |
| EP3193892A4 (en) | Personalized cancer vaccines and methods therefor | |
| SG11201608605QA (en) | Methods and means for enhancing rna production | |
| PL3110975T3 (en) | Methods for analysis of somatic mobile elements, and uses thereof | |
| HK1223562A1 (en) | Ligand cytotoxic drug conjugates, preparation method therefor, and uses thereof | |
| IL252430A0 (en) | Antibodies, uses and methods | |
| HUE049533T2 (en) | Polycarbonate copolymer and preparation method therefor | |
| SG10202006863YA (en) | Cl and/or ch1 mutated antibodies for drug conjugation | |
| EP3395366C0 (en) | Drug design method, obtained drug and application thereof | |
| LU92659B1 (en) | Glycooptimized antibody drug conjugates | |
| SG11201702076WA (en) | Cancer evaluation method and cancer evaluation system | |
| EP3134545A4 (en) | Method and biomarker for detecting cancer | |
| HK1231405A1 (en) | Methods and compositions for screening and detecting cancer | |
| EP3434765A4 (en) | Anti-tmem-180 antibody, anticancer agent, and test method for cancer | |
| GB201405715D0 (en) | Methods, apparatus and materials | |
| EP3184635A4 (en) | Cancer marker and cancer determination method | |
| EP3122375A4 (en) | Breast and ovarian cancer vaccines | |
| SG11201702260RA (en) | Anti-cancer agent and cancer cell killing method | |
| IL257514A (en) | Cancer detection method |